Connect with us

Technology

LetsGetChecked valued at $1bn after $150m funding round

Published

on

The health tech start-up has pushed into coronavirus testing and will now expand into additional virtual care services.

LetsGetChecked, the Irish home health testing kit start-up, is now valued at more than $1bn after its latest funding round.

The company has raised $150m in a Series D round led by Casdin Capital with pro golfer Rory McIlroy investing again.

The rest of the investment comes from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners and Qiming Venture Partners USA.

LetsGetChecked, founded in 2015, builds and delivers at-home testing kits, including hormone tests, fertility tests, HPV tests and wellness tests for cholesterol or diabetes. Tests are carried out at home using the kits with samples sent to a lab for analysis and results.

It entered the market for Covid-19 tests last year after securing FDA authorisation.

Support Silicon Republic

According to the company, it served more than 1m customers over the last year and has delivered more than 2m tests. It reaches both consumers and enterprise clients with 300 large companies using its services including American Airlines, which used the Covid-19 kits for pre-flight tests.

The company is now diversifying into virtual care services for the post-pandemic world. This will include telehealth services that allow for virtual consultations with a “LetsGetChecked-affiliated provider” to discuss test results or a prescription.

It is doubling down on prescription services and is currently acquiring a pharmacy in Jupiter, Florida. The company has placed a great deal of focus on expanding in the US.

“Now more than ever, we are seeing unprecedented demand for at-home diagnostics and care as an alternative to traditional in-person medical visits,” chief executive Peter Foley said.

“At LetsGetChecked, we are moving beyond just providing services that empower consumers to take agency over their own health. We are expanding into new offerings like telehealth services and prescriptions to even further fulfil our mission to help people live longer, happier lives.”

Last year the company raised $71m and announced plans for 160 jobs in Dublin, where its recently opened lab services the European market. There is a total of 650 employees across the company’s Dublin and New York bases.

Source link

Technology

2021 iPhone photography awards – in pictures | Technology

Published

on

The 14th annual iPhone photography awards offer glimpses of beauty, hope and the endurance of the human spirit. Out of thousands of submissions, photojournalist Istvan Kerekes of Hungary was named the grand prize winner for his image Transylvanian Shepherds. In it, two rugged shepherds traverse an equally rugged industrial landscape, bearing a pair of lambs in their arms.

Source link

Continue Reading

Technology

With Alphabet’s legendary commitment to products, we can’t wait to see what its robotics biz Intrinsic achieves • The Register

Published

on

Alphabet today launched its latest tech startup, Intrinsic, which aims to build commercial software that will power industrial robots.

Intrinsic will focus on developing software control tools for industrial robots used in manufacturing, we’re told. Its pitch is that the days of humans having to manually program and adjust a robot’s every move are over, and that mechanical bots should be more autonomous and smart, thanks to advances in artificial intelligence and leaps in training techniques.

This could make robots easier to direct – give them a task, and they’ll figure out the specifics – and more efficient – the AI can work out the best way to achieve its goal.

“Over the last few years, our team has been exploring how to give industrial robots the ability to sense, learn, and automatically make adjustments as they’re completing tasks, so they work in a wider range of settings and applications,” said CEO Wendy Tan White.

“Working in collaboration with teams across Alphabet, and with our partners in real-world manufacturing settings, we’ve been testing software that uses techniques like automated perception, deep learning, reinforcement learning, motion planning, simulation, and force control.”

Tan White – a British entrepreneur and investor who was made an MBE by the Queen in 2016 for her services to the tech industry – will leave her role as vice president of X, Alphabet’s moonshot R&D lab, to concentrate on Intrinsic.

She earlier co-founded and was CEO of website-building biz Moonfruit, and helped multiple early-stage companies get up and running as a general partner at Entrepreneur First, a tech accelerator. She is also a board trustee of the UK’s Alan Turing Institute, and member of Blighty’s Digital Economic Council.

“I loved the role I played in creating platforms that inspired the imagination and entrepreneurship of people all over the world, and I’ve recently stepped into a similar opportunity: I’m delighted to share that I’m now leading Intrinsic, a new Alphabet company,” she said.

The new outfit is another venture to emerge from Google-parent Alphabet’s X labs, along with Waymo, the self-driving car startup; and Verily, a biotech biz. ®

Source link

Continue Reading

Technology

Charles River to create 90 new jobs at Ballina biologics site

Published

on

Charles River is expanding its testing capabilities in Ballina as part of its partnership with Covid-19 vaccine manufacturer AstraZeneca.

Contract research organisation Charles River Laboratories is planning an €8m site expansion in Ballina to facilitate batch release testing for Covid-19 vaccines from AstraZeneca.

The expansion at the Mayo site will create an additional 1,500 sq m of lab space and 90 highly skilled jobs in the area over the next three years.

Click here to check out the top sci-tech employers hiring right now.

The company provides longstanding partners AstraZeneca with outsourced regulated safety and development support on a range of treatments and vaccines, including testing and facilitating the deployment of Vaxzevria for Covid-19 and Fluenz for seasonal infleunza.

The latest investment follows earlier expansions at the Ballina site and Charles River recently announced plans to establish a dedicated laboratory space to handle testing of SARS-CoV-2 and other similar pathogens that cause human disease.

“We are incredibly proud of the transformational changes we have implemented on site and the role that Charles River has played in supporting the safe and timely roll-out of AstraZeneca’s Covid-19 vaccine,” said Liam McHale, site director for Charles River Ballina.

“Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients.”

Charles River acquired the Ballina facility, which focuses on biologics testing, in 2002. The company employs 230 people at its two facilities in Ireland, including the Mayo site and a site in Dublin, established in 2017, which serves as the EMEA and APAC headquarters for the company’s microbial solutions division.

IDA Ireland is supporting the expansion. Mary Buckley, executive director of the agency, said Charles River is an “employer of long standing” in Co Mayo.

“The enhancement of its product lines and the development of additional capability at the Ballina facility is most welcome,” she added. “Today’s announcement is strongly aligned to IDA Ireland’s regional pillar and its continued commitment to winning jobs and investment in regional locations.”

Dan Wygal, country president for AstraZeneca Ireland, added: “Our Covid-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. We are committed to bringing safe, effective vaccines to Ireland and other markets as quickly as possible, and Charles River will continue to be an important partner in this regard.”

Source link

Continue Reading

Trending

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates 
directly on your inbox.

You have Successfully Subscribed!